idarubicin has been researched along with busulfan in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 8 (23.53) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| de Witte, T; Jerjis, S; Muus, P; Roovers, E; Schaap, N | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Baccarani, M; Damiani, D; Fanin, R; Geromin, A; Patriarca, F; Sperotto, A | 1 |
| Capria, S; Ferrazza, G; Mandelli, F; Meloni, G; Micozzi, A; Petrucci, MT; Simone, F; Trasarti, S; Trisolini, SM | 1 |
| Cavenagh, JD; Kelsey, SM; Lillington, DM; McBride, NC; Murrell, C; Newland, AC | 1 |
| Arcese, W; Cimino, G; De Felice, L; Girelli, G; Girmenia, C; Gozzer, M; Guglielmi, C; Iori, AP; Mandelli, F; Mengarelli, A; Perrone, MP; Ricci, R; Testi, AM | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Annunziata, M; Copia, C; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pollio, F; Russo, C; Schiavone, EM; Viola, A | 1 |
| Clark, AD; Cook, G; Douglas, KW; Franklin, IM; McQuaker, IG; Mitchell, LD; Parker, AN; Tansey, PJ | 1 |
| Annunziata, M; Califano, C; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Viola, A | 1 |
| De Simone, M; Fasanaro, A; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Sagristani, M; Viola, A | 1 |
| Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Palmieri, S; Pedata, M; Viola, A | 1 |
| Copia, C; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Musto, P; Palmieri, S; Pedata, M; Riccardi, C | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Muccioli, G; Palmieri, S; Pane, F; Riccardi, C; Viola, A | 1 |
| Fang, J; Hong, M; Hu, C; Hu, Y; Wu, Q; Xia, L; You, Y; Zhong, Z; Zou, P | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Chen, LJ; Hong, M; Li, JY; Liu, P; Lu, H; Miao, KR; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R; Zhang, SJ | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Fang, J; Hong, M; Hu, Y; Li, W; Nie, D; Wang, H; Wu, Q; Xia, L; You, Y; Zhang, R; Zhong, Z | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Fan, Z; Huang, F; Li, X; Lin, D; Lin, R; Liu, H; Liu, Q; Liu, X; Shi, P; Sun, J; Sun, Z; Wang, Z; Wu, M; Xiong, Y; Xu, J; Xu, N; Xuan, L; Zhang, Y | 1 |
1 review(s) available for idarubicin and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 trial(s) available for idarubicin and busulfan
| Article | Year |
|---|---|
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 1998 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Stroke Volume; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2001 |
Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Recombinant Proteins; Survival Rate; Treatment Outcome | 2002 |
Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Topics: Acute Disease; Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Secondary Prevention; Survival Rate; Transplantation Conditioning | 2004 |
High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2005 |
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2009 |
High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?
Topics: Adolescent; Adult; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Transplantation Conditioning | 2023 |
20 other study(ies) available for idarubicin and busulfan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors | 1996 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Macroglossia; Melphalan; Middle Aged; Purpura; Transplantation, Autologous; Treatment Outcome; Vincristine | 1999 |
Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Middle Aged; Transplantation, Homologous; Treatment Outcome | 2000 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Dacarbazine; Female; Graft Survival; Humans; Idarubicin; Infections; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neutropenia; Nimustine; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2006 |
Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Prognosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Young Adult | 2010 |
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chimerism; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2012 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2016 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |